Editas Medicine, Inc. (NASDAQ:EDIT) Logo

Editas Medicine (NASDAQ:EDIT) Stock Upgrade

BidaskScore has upgraded shares of Editas Medicine (NASDAQ:EDIT) to a solid Sell in an analyst note issued to clients and investors on today.

The stock increased 3.00% or $0.85 during the last trading session, reaching $29.23. About 1.86 million shares traded or 164.72% up from the average. Editas Medicine, Inc. (NASDAQ:EDIT) has declined 14.14% since November 29, 2018 and is downtrending. It has underperformed by 14.14% the S&P500.

Analysts await Editas Medicine, Inc. (NASDAQ:EDIT) to report earnings on February, 27. They expect $0.04 EPS, up 107.69 % or $0.56 from last year’s $-0.52 per share. EDIT’s profit will be $2.05M for 182.69 P/E if the $0.04 EPS becomes a reality. After $-0.66 actual EPS reported by Editas Medicine, Inc. for the previous quarter, Wall Street now forecasts -106.06 % EPS growth.

Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $1.50 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

More notable recent Editas Medicine, Inc. (NASDAQ:EDIT) news were published by: Nasdaq.com which released: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” on November 26, 2019, also Nasdaq.com with their article: “Rail Strike at Canadian National Calls for Lay-offs in Halifax – Nasdaq” published on November 26, 2019, Nasdaq.com published: “CRISPR vs. Gene Therapy Round 1: What Investors Need to Know – Nasdaq” on November 26, 2019. More interesting news about Editas Medicine, Inc. (NASDAQ:EDIT) were released by: Nasdaq.com and their article: “2 Headwinds to Restaurant Brands International’s Expansion – Nasdaq” published on November 22, 2019 as well as Nasdaq.com‘s news article titled: “Why Editas Medicine Shares Jumped Today – Nasdaq” with publication date: November 25, 2019.

Editas Medicine, Inc. (NASDAQ:EDIT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link